OOIR: Observatory of International Research

Papers

(The H4-Index of Neurology and Therapy is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Study	428
Correction to: Off-time Treatment Options for Parkinson’s Disease	116
Letter to the Editor regarding “COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Stu	81
Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study	66
Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications	60
Persistence to Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis: Results from the German NeuroTransData Registry	56
Characteristics of Postural Instability in Idiopathic Normal Pressure Hydrocephalus	53
Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis in France: The TITAN Study	52
Methotrexate and the Risk of Dementia: A Two-Sample Mendelian Randomization Study	48
Sudoscan in ATTRv Amyloidosis: A Potential Marker of Disease Progression?	47
Expert Guidance on Cognitive Impairment in Alzheimer's Disease: A Practical Seven-Step Approach from the United Arab Emirates	45
Therapeutic Decision-Making Under Uncertainty in the Management of Spinal Muscular Atrophy: Results From DECISIONS-SMA Study	44
Association Between Serum Neurofilament Light Chain and Cognitive Performance Among Older Adults in the United States: A Cross-Sectional Study	43
The European Lambert–Eaton Myasthenic Syndrome Registry: Long-Term Outcomes Following Symptomatic Treatment	43
Plasticity-Induced Motor Recovery of Bilateral Intermittent Theta Burst Stimulation in Parkinson’s Disease: A Randomized, Double-Blind, Sham-Controlled, Crossover Trial	38
No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis	36
Selective S1P Receptor Modulation in Multiple Sclerosis Alters CXCL13:CXCR5-Associated Immune Activities Without Impacting Anti-SARS-CoV-2 Immunity	35
Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke	34
Clinical Spectrum of Acquired Demyelinating Syndromes in Children: A Tertiary Hospital Experience	32
Use of Stiripentol in Patients with Dravet Syndrome: Common Practice Among Experts in Spain	32
The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy	29
Clinical Study of Limosilactobacillus reuteri for the Treatment of Children with Chronic Tic Disorders/Tourette Syndrome: A Mid-Term Efficacy Evaluation	29
Impact of Istradefylline on Levodopa Dose Escalation in Parkinson’s Disease: ISTRA ADJUST PD Study, a Multicenter, Open-Label, Randomized, Parallel-Group Controlled Study	29
Machine Learning for Predicting Thromboembolic Events Following Flow Diverter Treatment of Intracranial Aneurysms: A Multicenter Retrospective Study	28
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study	28

Pacemaker Implants and Their Influence on the Daily Life of Patients with Dementia with Lewy Bodies: A Qualitative Case Study	28
Dietary Patterns and Their Associations with Symptom Levels Among People with Multiple Sclerosis: A Real-World Digital Study	27